N-(4-(dimethylamino)butyl)-4-(((2,6-dimethylpyrimidin-4-yl)(neopentyl)amino)methyl)benzamide

ID: ALA4059983

PubChem CID: 132607371

Max Phase: Preclinical

Molecular Formula: C25H39N5O

Molecular Weight: 425.62

Molecule Type: Small molecule

Names and Identifiers

Canonical SMILES:  Cc1cc(N(Cc2ccc(C(=O)NCCCCN(C)C)cc2)CC(C)(C)C)nc(C)n1

Standard InChI:  InChI=1S/C25H39N5O/c1-19-16-23(28-20(2)27-19)30(18-25(3,4)5)17-21-10-12-22(13-11-21)24(31)26-14-8-9-15-29(6)7/h10-13,16H,8-9,14-15,17-18H2,1-7H3,(H,26,31)

Standard InChI Key:  VSYMZQSLKZVQCX-UHFFFAOYSA-N

Molfile:  

     RDKit          2D

 31 32  0  0  0  0  0  0  0  0999 V2000
   15.5376   -5.1425    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   15.5365   -5.9662    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   16.2486   -6.3751    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   16.9624   -5.9657    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   16.9596   -5.1389    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   16.2468   -4.7295    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   16.2444   -3.9082    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   16.9550   -3.4975    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   15.5313   -3.5017    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   15.5289   -2.6804    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.8159   -2.2698    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   16.2395   -2.2656    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   17.6639   -3.9040    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   17.6642   -4.7226    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   18.3764   -5.1332    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   19.0880   -4.7183    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   19.0829   -3.8927    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   18.3702   -3.4900    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   19.7995   -5.1243    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.8289   -6.3751    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   15.5225   -1.8614    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   17.6702   -6.3741    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   19.8036   -5.9415    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   20.5052   -4.7122    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   21.2149   -5.1172    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   21.9206   -4.7051    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   22.6303   -5.1101    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   23.3360   -4.6980    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   24.0457   -5.1030    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   24.7514   -4.6909    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   24.0498   -5.9202    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  2  0
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  2  0
  6  1  1  0
  6  7  1  0
  7  8  1  0
  7  9  1  0
  9 10  1  0
 10 11  1  0
 10 12  1  0
  8 13  1  0
 13 14  2  0
 14 15  1  0
 15 16  2  0
 16 17  1  0
 17 18  2  0
 18 13  1  0
 16 19  1  0
  2 20  1  0
 10 21  1  0
  4 22  1  0
 19 23  2  0
 19 24  1  0
 24 25  1  0
 25 26  1  0
 26 27  1  0
 27 28  1  0
 28 29  1  0
 29 30  1  0
 29 31  1  0
M  END

Alternative Forms

1. Parent:

   

   ALA4059983

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 425.62

Molecular Weight (Monoisotopic): 425.3155

AlogP: 4.22

#Rotatable Bonds: 10

Polar Surface Area: 61.36

Molecular Species: BASE

HBA: 5

HBD: 1

#RO5 Violations: ┄

HBA (Lipinski): 6

HBD (Lipinski): 1

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: ┄

CX Basic pKa: 9.49

CX LogP: 4.53

CX LogD: 2.31

Aromatic Rings: 2

Heavy Atoms: 31

QED Weighted: 0.58

Np Likeness Score: -1.44

References

1. Miltz W, Velcicky J, Dawson J, Littlewood-Evans A, Ludwig MG, Seuwen K, Feifel R, Oberhauser B, Meyer A, Gabriel D, Nash M, Loetscher P..  (2017)  Design and synthesis of potent and orally active GPR4 antagonists with modulatory effects on nociception, inflammation, and angiogenesis.,  25  (16): [PMID:28689977] [10.1016/j.bmc.2017.06.050]

Source

Source(1):

• Scientific Literature